# Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

> **NCT04892264** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 5 (actual)

## Conditions studied

- Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Belantamab Mafodotin
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Skeletal Survey X-Ray
- **PROCEDURE:** Low Dose Computed Tomography of the Whole Body
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy

## Key facts

- **NCT ID:** NCT04892264
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-03
- **Primary completion:** 2024-03-18
- **Final completion:** 2024-03-18
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low/slow accrual - did not proceed to Phase 2
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892264, "Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04892264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*